MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Rating of “Buy” by Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Several brokerages recently weighed in on MDXG. StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a report on Thursday, August 1st. Finally, Craig Hallum dropped their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MDXG. Headlands Technologies LLC bought a new position in shares of MiMedx Group during the 1st quarter valued at about $27,000. Isthmus Partners LLC boosted its holdings in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of MiMedx Group during the 2nd quarter valued at about $40,000. Quest Partners LLC bought a new position in shares of MiMedx Group during the 2nd quarter valued at about $81,000. Finally, Entropy Technologies LP bought a new position in shares of MiMedx Group during the 1st quarter valued at about $99,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Trading Up 3.2 %

Shares of MDXG stock opened at $5.83 on Monday. MiMedx Group has a 1 year low of $5.57 and a 1 year high of $9.27. The firm has a fifty day moving average price of $6.53 and a 200-day moving average price of $6.94. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.85 and a quick ratio of 3.22. The company has a market cap of $855.90 million, a price-to-earnings ratio of 13.25 and a beta of 1.98.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. The firm had revenue of $87.21 million during the quarter, compared to the consensus estimate of $88.44 million. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. As a group, equities analysts predict that MiMedx Group will post 0.26 earnings per share for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.